News & Updates

Patients with type 2 diabetes (T2D) who initiated treatment with empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), and a glucagon-like peptide-1 receptor agonist (GLP-1RA) show reduced hospitalization for heart failure (HHF) and all-cause mortality risks relative to those treated with empagliflozin and dipeptidyl peptidase-4 inhibitors (DPP-4i), reports a study presented at EASD 2024.

Use of glucagon-like peptide-1 receptor agonists (GLP-1RA) among patients with type 2 diabetes (T2D) appears to have protective benefits against the development of glaucoma compared with exposure to other second-line antihyperglycaemic medications, according to a study.

Another feather may have been added in the cap of glucagon-like protein-1 receptor agonists (GLP-1 RAs) – the class of type 2 diabetes (T2D) drugs that has become a blockbuster recently due to their remarkable weight loss benefit – as evidence of their potential to reduce the risk of obesity-associated cancers (OACs) comes to light.

COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.

Higher consumption of raw cruciferous vegetables appears to reduce the risk of recurrence in nonmuscle-invasive bladder cancer (NMIBC) patients treated with induction bacillus Calmette-Guérin (BCG), suggests a study.

Treatment with canagliflozin results in clinically meaningful reductions in glycated haemoglobin (HbA1c), when compared with placebo, in children and adolescents with type 2 diabetes (T2D), as shown by the results of a phase III study presented at EASD 2024.